In February 2013, the Global Fund announced a new funding model – moving away from its rounds-based, competitive approach to ‘‘invest more strategically, achieve greater impact, and engage implementers and partners more effectively’’ (Global Fund, 2013). Under this new model, the Global Fund determines funding allocations for each eligible country based on calculations of country income and national disease burden. Additional funding has also been set aside for regional proposals. This article employs the same methodology from previous analyses of Global Fund investments in harm reduction (Bridge et al., 2012), thus providing a complete dataset for the entire duration of the Global Fund’s rounds-based funding model – from Round 1 (2002) to the Transitional Funding Mechanism that replaced Round 11 (2011).
Keep up-to-date with drug policy developments by subscribing to the IDPC Monthly Alert.